Special Issue "Personalized Medicine for Coronary Artery Disease: Diagnosis, Prevention, and Treatment"
Deadline for manuscript submissions: 30 September 2023 | Viewed by 8012
Interests: ubiquitin proteasome; oncology; stents; apoptosis; cardiology; ubiquitination; coronary artery disease; vascular medicine; PCI
Special Issues, Collections and Topics in MDPI journals
Special Issue in Journal of Personalized Medicine: Personalized Medicine of Coronary Artery Disease
Special Issue in Pharmaceuticals: Drug-Induced Cardiotoxicity 2023
We can define personalized medicine as diagnostic and screening methods to better manage an individual patient’s disease or their predisposition toward disease. A remarkable progression of genomic studies has been achieved in recent decades, from the characterization of the deoxyribonucleic acid (DNA) double helix by Watson and Crick in 1953, to completing the Human Genome Project in 2003. The Human Genome Project and International HapMap Project provided a tremendous amount of information based on DNA.
Moreover, individualized medicine represents another stage in the development of personalized medicine. While personalized medicine is aimed at a specific group of patients, individualized medicine deals with the individual circumstances of a single person. Thus, individualized medicine goes one step further and can be considered an increase in the specificity of personalized medicine. Individualized medicine not only looks at genes but also focuses on the full range of a person's unique nature, including biological, physiological, and anatomical information.
As far as coronary artery disease is concerned, traditional risk factors fail to explain up to 50% of morbidity and mortality. Moreover, both the conventional and novel risk factors have a partial genetic origin. Many studies have shown that treatment algorithms supported by consensus guidelines may lead to a situation where a significant percentage of patients (such as patients with no Apo E genotype) are treated sub-optimally. Therefore, limiting disease management to the “one diet and standard drug therapy regimen fits all” approach is not the best option.
Recent studies suggest that the transformation of medicine in the 21st century can be called “P4 Medicine”, i.e., Predictive, Personalized, Preemptive, and Participatory. Moreover, the genome record might allow physicians to make treatment decisions based on patient genotypes. This might enable individuals to make appropriate lifestyle choices as well as to use proper drugs.
Personalized medicine is developing fast, and new data are emerging in huge amounts. This might enable the proper risk assessment, diagnosis, prevention, and therapy specifically tailored to the individual's unique characteristics, thus enhancing the quality of life and public health. Therefore, this Special Issue aims to present recent developments in personalized/individualized medicine and coronary artery disease.
We invite authors to submit original studies, reviews, meta-analyses, and case reports focused on the individualization of the prevention, diagnosis, and treatment of coronary artery disease and its complications such as myocardial infarction or heart failure. We are soliciting not only genetic studies but all papers on the broadly understood personalized or individualized medicine, including manuscripts devoted to novel drugs, medical devices, or approaches dedicated to particular subsets of patients.
Dr. Jacek Bil
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- coronary artery disease
- CVD prevention
- targeted treatment
- gene-environment interaction
- residual cardiovascular risk